---
id: cytomegalovirus_104
category: organisms
tags: [CMV, cytomegalovirus, ganciclovir, valganciclovir, retinitis, HIV-OI]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Cytomegalovirus (CMV)

**Q:** What are the clinical manifestations, diagnosis, and treatment of CMV disease in immunocompromised patients (HIV, transplant) and congenital CMV infection?

**A:**

## OVERVIEW

**Organism:** Cytomegalovirus (CMV) - Human herpesvirus 5 (HHV-5)

**Transmission:**
- **Bodily fluids** (saliva, urine, blood, semen, breast milk)
- **Transplant** (donor organ/stem cells)
- **Transfusion** (blood products)
- **Congenital** (transplacental)

**Epidemiology:**
- **Seroprevalence:** 50-80% (US adults)
- **Latency:** Monocytes, endothelial cells (reactivates with immunosuppression)

---

## CLINICAL MANIFESTATIONS BY POPULATION

---

## 1. CMV IN HIV/AIDS

**Risk:** **CD4 <50 cells/μL** (85% have CD4 <50)

---

### **A. CMV Retinitis (Most Common End-Organ Disease in HIV):**

**Epidemiology:**
- **#1 cause of vision loss** in AIDS (pre-ART era)
- **Rare now** (ART era) but still occurs

**Clinical Features:**
- **Painless, progressive vision loss** (floaters, scotomas, decreased acuity)
- **Unilateral initially** → bilateral (80% if untreated)
- **NO pain, NO red eye** (unlike HSV keratitis, uveitis)

**Ophthalmoscopy Findings:**
- **"Pizza pie" or "cottage cheese and ketchup"** appearance
- **Yellow-white retinal infiltrates** with **hemorrhage** (along retinal vessels)
- **Granular appearance**

**Key Point:** **Painless vision loss + "pizza pie" retina + CD4 <50** = CMV retinitis

---

**Diagnosis:**
- **Clinical** (ophthalmoscopy by ophthalmologist)
- **Fundus photography** (document lesions, monitor response)
- **CMV PCR (blood):** High viral load supports diagnosis but NOT diagnostic

**Key Point:** **Diagnosis = clinical** (ophthalmoscopy findings)

---

**Treatment:**

**Induction Therapy (14-21 Days):**

| **Agent** | **Dosing** | **Route** |
|-----------|------------|-----------|
| **Valganciclovir** (preferred - oral) | **900 mg PO BID** | Oral |
| **OR Ganciclovir** | **5 mg/kg IV BID** | IV |
| **OR Foscarnet** | **90 mg/kg IV BID** OR **60 mg/kg IV q8h** | IV |

**For Sight-Threatening Lesions (Near Macula/Optic Nerve):**
- **Intravitreous ganciclovir** 2 mg/0.05 mL OR **foscarnet** 2.4 mg/0.1 mL (1-2x/week) + systemic therapy

---

**Maintenance Therapy (Chronic Suppression):**

| **Agent** | **Dosing** |
|-----------|------------|
| **Valganciclovir** (preferred) | **900 mg PO daily** |
| **OR Ganciclovir** | **5 mg/kg IV daily** |
| **OR Foscarnet** | **90-120 mg/kg IV daily** |

**Duration:** Until **immune reconstitution** (CD4 >100 x ≥3-6 months on ART + inactive lesions)

**Key Point:** **Valganciclovir = preferred** (oral, better bioavailability than oral ganciclovir)

---

**Adjunctive Therapy:**
- **ART initiation** (if not on ART): Start **1-2 weeks after anti-CMV therapy** (allow time for CMV treatment to work, prevent IRIS)

**Follow-Up:**
- **Ophthalmology exam:** At diagnosis, 2 weeks after starting therapy, then **monthly** while on treatment

---

### **B. CMV Colitis:**

**Clinical Features:**
- **Chronic diarrhea** (watery or bloody)
- **Abdominal pain, cramping**
- **Weight loss**
- **Fever** (50%)

**Diagnosis:**
- **Colonoscopy:** Mucosal ulcerations (linear, "punched-out")
- **Biopsy:** **"Owl's eye" inclusions** (intranuclear + intracytoplasmic)
- **Immunohistochemistry** OR **CMV PCR** (tissue)

**Key Point:** **Biopsy = gold standard** ("owl's eye" inclusions)

---

**Treatment:**

**Induction:**
- **Ganciclovir** 5 mg/kg IV BID OR **Valganciclovir** 900 mg PO BID (if mild + can absorb PO)
- **Duration:** 21-42 days (until resolution of symptoms)

**Key Point:** **IV ganciclovir preferred initially** (may have impaired GI absorption)

---

### **C. CMV Esophagitis:**

**Clinical Features:**
- **Odynophagia** (painful swallowing)
- **Substernal chest pain**
- **Nausea, vomiting**

**Diagnosis:**
- **EGD:** Large, **deep, well-demarcated ulcers** (typically distal esophagus)
- **Biopsy:** "Owl's eye" inclusions (at ulcer base)

---

**Treatment:**
- **Ganciclovir** 5 mg/kg IV BID OR **Valganciclovir** 900 mg PO BID
- **Duration:** 21-42 days

---

### **D. CMV Pneumonitis (Rare in HIV, More Common in Transplant):**

**Clinical Features:**
- **Dyspnea, cough, fever**
- **Hypoxemia**
- **Diffuse interstitial infiltrates** (CXR/CT)

**Treatment:**
- **Ganciclovir** 5 mg/kg IV BID (+ consider **CMV hyperimmune globulin** in transplant)

---

### **E. CMV Encephalitis/Ventriculoencephalitis:**

**Clinical Features:**
- **Altered mental status, confusion**
- **Cranial nerve palsies**
- **Nystagmus, ataxia**

**Diagnosis:**
- **CSF:** Pleocytosis (PMN or lymphocytic), elevated protein
- **CMV PCR (CSF):** Positive
- **MRI:** **Periventricular enhancement** (ventriculoencephalitis)

**Treatment:**
- **Ganciclovir** 5 mg/kg IV BID (or valganciclovir 900 mg PO BID) + **Foscarnet** 90 mg/kg IV BID (combination)

---

## 2. CMV IN SOLID ORGAN TRANSPLANT (SOT)

**Risk Factors:**
- **Donor CMV+ / Recipient CMV-** (highest risk - 50-80%)
- **Recipient CMV+** (reactivation - 20-30%)
- **High-level immunosuppression**

**Timing:** Typically **1-6 months post-transplant** (earlier if no prophylaxis)

---

### **Clinical Syndromes:**

**CMV Syndrome:**
- **Fever, malaise, leukopenia, thrombocytopenia**
- **No end-organ involvement**

**End-Organ Disease:**
- **Pneumonitis** (most common in lung transplant)
- **Hepatitis** (liver transplant)
- **Colitis**
- **Retinitis** (rare)

**Key Point:** **CMV pneumonitis = most serious** in transplant (high mortality)

---

**Diagnosis:**

| **Test** | **Use** | **Notes** |
|----------|---------|-----------|
| **CMV PCR (blood)** | **Preferred for monitoring** | **Quantitative** (viral load) |
| **CMV pp65 antigenemia** | Diagnosis | Less common now (replaced by PCR) |
| **Tissue biopsy** | End-organ disease | "Owl's eye" inclusions + IHC |

**Key Point:** **Quantitative CMV PCR = preferred** (monitor viral load, guide therapy)

---

**Treatment:**

**Mild-Moderate CMV Disease:**
- **Valganciclovir** 900 mg PO BID x 14-21 days (induction) → 900 mg PO daily (maintenance until viral load undetectable)

**Severe CMV Disease (Pneumonitis, High Viral Load, Impaired GI Absorption):**
- **Ganciclovir** 5 mg/kg IV BID x 14-21 days + **CMV hyperimmune globulin (CMV-IVIG)** (especially pneumonitis)

**CMV-IVIG Dosing (Pneumonitis):**
- **150 mg/kg IV** within 72h, then days 2, 4, 6, 8, then **100 mg/kg** weekly x 4 weeks

**Key Point:** **CMV-IVIG + ganciclovir** for CMV pneumonitis in transplant (reduces mortality)

---

**Prophylaxis (Transplant):**

**Universal Prophylaxis (All D+/R- or R+ Recipients):**
- **Valganciclovir** 900 mg PO daily x 3-6 months post-transplant (duration depends on organ type)

**Alternative: Preemptive Therapy:**
- **Monitor CMV PCR weekly** → Treat if viral load ↑ (before symptoms)

---

## 3. CMV IN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)

**Risk:** **Allogeneic HSCT > Autologous** (especially if GVHD, high immunosuppression)

**Timing:** Typically **1-4 months post-transplant**

---

**Clinical Syndromes:**
- **CMV syndrome** (fever, leukopenia)
- **CMV pneumonitis** (most serious - 50-80% mortality if untreated)
- **CMV colitis**

---

**Diagnosis & Treatment:**
- **Preemptive therapy** (monitor CMV PCR weekly → treat if detectable)
- **Ganciclovir** 5 mg/kg IV BID OR **Foscarnet** 90 mg/kg IV BID (if ganciclovir-resistant or neutropenic)
- **CMV-IVIG** (if pneumonitis)

---

## 4. CONGENITAL CMV INFECTION

**Epidemiology:**
- **Most common congenital infection** (0.5-0.7% live births)
- **Leading cause of non-genetic sensorineural hearing loss**

**Transmission:**
- **Primary maternal infection** during pregnancy (higher risk) OR reactivation/reinfection

---

### **Clinical Features:**

**Symptomatic at Birth (10-15%):**
- **Petechiae, purpura** ("blueberry muffin" baby)
- **Jaundice, hepatosplenomegaly**
- **Microcephaly**
- **Intracranial calcifications** (periventricular - vs Toxo = diffuse)
- **Chorioretinitis**
- **Sensorineural hearing loss (SNHL)**
- **Seizures**

**Asymptomatic at Birth (85-90%):**
- **10-15% develop late sequelae:**
  - **Sensorineural hearing loss** (most common - progressive)
  - **Developmental delay, intellectual disability**
  - **Vision impairment**

**Key Point:** **Periventricular calcifications** = congenital CMV (vs Toxo = diffuse)

---

**Diagnosis:**

**Definitive Diagnosis (Must Be Within First 3 Weeks of Life):**
- **CMV PCR** (urine, saliva, or blood) OR **viral culture** (urine, saliva)
- **After 3 weeks:** Cannot distinguish congenital vs postnatal infection

**Imaging:**
- **Head ultrasound/CT:** Periventricular calcifications, ventriculomegaly

**Key Point:** **Diagnose within 3 weeks** of birth (urine/saliva CMV PCR)

---

**Treatment:**

**Indications:**
- **Symptomatic congenital CMV** (especially with **CNS involvement** or **moderate-severe disease**)
- **Isolated sensorineural hearing loss**

**Regimen:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Valganciclovir** (oral suspension) | **16 mg/kg PO BID** | **6 months** |
| **OR Ganciclovir** (if cannot tolerate PO) | **6 mg/kg IV BID** | 6 months |

**Benefits:**
- **Improves hearing outcomes** (prevents progression of SNHL)
- **Improves neurodevelopmental outcomes**

**Adverse Effects:**
- **Neutropenia** (monitor CBC weekly initially)
- **Hepatotoxicity**

**Key Point:** **Treat symptomatic congenital CMV** with valganciclovir x 6 months (start before 1 month of age)

---

## GANCICLOVIR-RESISTANT CMV

**Risk Factors:**
- **Prolonged ganciclovir exposure** (>3 months)
- **Subtherapeutic levels** (poor adherence, malabsorption)
- **Severe immunosuppression** (CD4 <50, high-dose immunosuppression)

**Diagnosis:**
- **Persistent/rising CMV viral load** despite ganciclovir therapy
- **Genotypic resistance testing** (UL97, UL54 mutations)

---

**Treatment:**

| **Agent** | **Dosing** | **Notes** |
|-----------|------------|-----------|
| **Foscarnet** | **90 mg/kg IV BID** (induction) → **90-120 mg/kg IV daily** (maintenance) | **Nephrotoxic** (aggressive hydration, monitor Cr) |
| **Cidofovir** | **5 mg/kg IV weekly x 2** → **5 mg/kg IV every 2 weeks** (maintenance) | **Nephrotoxic** (require probenecid + IV saline) |
| **Maribavir** (oral) | **400 mg PO BID** | **FDA 2021** (refractory/resistant CMV in transplant)<br>Superior to foscarnet/cidofovir |

**Key Point:** **Maribavir = oral option** for refractory/resistant CMV (55% clearance vs 24% conventional therapy)

---

## ADVERSE EFFECTS OF CMV ANTIVIRALS

| **Drug** | **Major Adverse Effects** | **Monitoring** |
|----------|---------------------------|----------------|
| **Ganciclovir/Valganciclovir** | **Bone marrow suppression** (neutropenia, thrombocytopenia, anemia) | CBC (2x/week initially, then weekly) |
| **Foscarnet** | **Nephrotoxicity**, electrolyte abnormalities (hypocalcemia, hypomagnesemia, hypokalemia) | Cr, electrolytes (2-3x/week)<br>Aggressive hydration |
| **Cidofovir** | **Nephrotoxicity** (proximal tubular damage) | Cr, urinalysis<br>Probenecid + IV saline (required) |

**Key Point:** **Ganciclovir = neutropenia** (avoid with AZT), **Foscarnet/Cidofovir = nephrotoxic**

---

## COMPARISON TABLE

| **Feature** | **CMV in HIV** | **CMV in Transplant** | **Congenital CMV** |
|-------------|----------------|----------------------|---------------------|
| **Risk** | CD4 <50 | D+/R-, high immunosuppression | Primary maternal infection (pregnancy) |
| **Most common manifestation** | **Retinitis** | **Pneumonitis** (lung transplant), syndrome | **Asymptomatic** (85-90%) |
| **Diagnosis** | Clinical (retinitis), biopsy (GI) | **Quantitative CMV PCR** (blood) | **CMV PCR** (urine/saliva) within 3 weeks |
| **Treatment** | Valganciclovir 900 mg BID (induction) → daily (maintenance) | Valganciclovir 900 mg BID OR Ganciclovir IV + **CMV-IVIG** (if pneumonitis) | **Valganciclovir 16 mg/kg BID x 6 months** (if symptomatic) |

---

**Mnemonic: "CMV Retinitis = Pizza Pie + CD4 <50 (Painless Vision Loss)"**
- **C**MV retinitis
- **P**izza pie appearance (yellow-white infiltrates + hemorrhage)
- **P**ainless vision loss
- CD4 <50

**Mnemonic: "Owl's Eye = CMV (Inclusions in Biopsy)"**
- **O**wl's eye inclusions
- **C**MV (intranuclear + intracytoplasmic)
- Biopsy (colitis, esophagitis, pneumonitis)

**Mnemonic: "CMV Pneumonitis in Transplant = Ganciclovir + CMV-IVIG"**
- **C**MV pneumonitis
- **G**anciclovir + **CMV-IVIG** (reduces mortality)
- Transplant patients

**Clinical Pearls:**
- **CMV retinitis = painless vision loss + "pizza pie" retina + CD4 <50**
- **Diagnosis = clinical** (ophthalmoscopy by ophthalmologist)
- **Valganciclovir = preferred** (oral, better bioavailability)
- **Start ART 1-2 weeks after anti-CMV therapy** (prevent IRIS)
- **Monthly ophthalmology exams** while on treatment
- **Discontinue maintenance** if CD4 >100 x ≥3-6 months + inactive lesions
- **CMV colitis/esophagitis:** "Owl's eye" inclusions on biopsy (gold standard)
- **IV ganciclovir preferred initially** for GI CMV (impaired absorption)
- **CMV in transplant:** Quantitative CMV PCR = preferred monitoring tool
- **CMV pneumonitis in transplant:** Ganciclovir + CMV-IVIG (reduces mortality)
- **Universal prophylaxis** (transplant): Valganciclovir 900 mg PO daily x 3-6 months
- **Congenital CMV = periventricular calcifications** (vs Toxo = diffuse)
- **Diagnose congenital CMV within 3 weeks** of birth (urine/saliva PCR)
- **Treat symptomatic congenital CMV** with valganciclovir 16 mg/kg BID x 6 months
- **Ganciclovir-resistant CMV:** Foscarnet OR cidofovir OR **maribavir** (oral, FDA 2021)
- **Maribavir superior** to foscarnet/cidofovir for resistant CMV (55% vs 24% clearance)
- **Ganciclovir = neutropenia**, **foscarnet/cidofovir = nephrotoxic**

**Media:** None

**Sources:** [NIH/HIVMA 2024 - CMV disease in HIV/AIDS], [IDSA 2024 - CMV in transplantation], [Lancet 2024 - Congenital CMV consensus], [NEJM 2024 - Maribavir for resistant CMV], [FDA 2021 - Maribavir approval], [Current Opinion Organ Transplantation 2024 - CMV management updates]
